Incannex Healthcare Inc. (IXHL): Cash & Equivalents

Annual figures by period end, from SEC filings.

$67.71M
As of 2026-06-30
$68.27M
As of 2026-09-30
+45.2%
3-year compound annual growth
2023-06-30: $22.12M2024-06-30: $5.86M2025-06-30: $15.04M2026-06-30: $67.71M$67.71M
2023-06-30 Cash & Equivalents (USD) 2026-06-30
Period endedCash & EquivalentsChange YoYSource filing
2026-06-30$67.71M+350.2%2026-09-25, Balance as of period end
2025-06-30$15.04M+156.7%2026-09-25, Balance as of period end
2024-06-30$5.86M-73.5%2025-09-29, Balance as of period end
2023-06-30$22.12Mn/a2024-09-30, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Incannex Healthcare Inc. (IXHL)2026-06-30$67.71M+350.2%
Abbott Laboratories (ABT)2025-12-31$8.52B+11.9%
Bristol Myers Squibb Co (BMY)2025-12-31$10.21B-1.3%
Eli Lilly & Co (LLY)2025-12-31$7.27B+122.4%
Pfizer Inc (PFE)2025-12-31$1.14B+9.5%
Johnson & Johnson (JNJ)2025-12-28$19.71B-18.2%
Nature's Sunshine Products Inc (NATR)2025-12-31$93.89M+10.9%
Merck & Co., Inc. (MRK)2025-12-31$14.56B+10.0%
Provectus Biopharmaceuticals, Inc. (PVCT)2025-12-31$251.3K-18.3%

Compare IXHL, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗